Efficacy of scopolamine transdermal patch in children with sialorrhea in a pediatric tertiary care hospital

Drooling is common in children with neurological disorders, but its management is very challenging, Scopolamine transdermal patch (STP) appears to be useful in controlling drooling, although it is not approved for this indication and there are limited clinical studies about its effectiveness. This s...

Full description

Saved in:
Bibliographic Details
Published in:BMC pediatrics 2020-09, Vol.20 (1), p.437-437, Article 437
Main Authors: Al Jeraisy, Majed, AlFuraih, Maissa, AlSaif, Raghad, AlKhalifah, Bushra, AlOtaibi, Hazza, Abolfotouh, Mostafa A
Format: Article
Language:English
Subjects:
Adolescent
Botulinum toxin
Caregivers
Cerebral Palsy
Child
Child health
Child, Preschool
Children
Comorbidity
Demographics
Disability
Drooling
Drug dosages
Efficacy
Families & family life
FDA approval
Hospitals
Humans
Hyoscine
Medical records
Medical research
Nervous system diseases
Parents & parenting
Patients
Pediatrics
Retrospective Studies
Saudi
Saudi Arabia
Scopolamine
Sialorrhea - drug therapy
Sialorrhea - etiology
Tertiary Care Centers
Transdermal
Transdermal drug delivery systems
Transdermal Patch
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drooling is common in children with neurological disorders, but its management is very challenging, Scopolamine transdermal patch (STP) appears to be useful in controlling drooling, although it is not approved for this indication and there are limited clinical studies about its effectiveness. This study aimed (1) to assess the impact of STP use on the severity of drooling and on the frequency of emergency department (ED) and hospital readmission (RA) visits related to drooling, and (2) to determine the level of family satisfaction with STP when used in children with neurological disorders. This is a retrospective cohort study of all pediatric patients aged 3-14 years, with non-progressive neurodevelopmental disability, who used STP for more than one year during the period between April 2015 and July 2018 (n = 44). Data on demographics, clinical status, comorbidities, STP dose and duration, other medications, ED and RA visits were collected. Follow-up phone-call interviews with parents/caregivers were performed using a parent-reported frequency and severity rating scale of sialorrhea. Absolute and relative risk reductions were calculated to assess the impact of STP on ED and RA visits. Significance was considered at p-value of ≤ 0.05. STP use showed significant reduction in severity of drooling (p 
ISSN:1471-2431
1471-2431
DOI:10.1186/s12887-020-02336-x